ADMA Biologics, Inc. (ADMA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 42 | 81 | 154 | 258 | 426 | 510 | 512 | 535 |
| Operating profit | $m | 191 | 217 | ||||||
| Net profit | $m | -76 | -72 | -66 | -28 | 198 | 147 | 169 | 195 |
| EPS reported | $ | 0.60 | 0.70 | ||||||
| Operating cashflow per share | $ | 0.21 | 0.60 | ||||||
| Capex per share | $ | 0.09 | 0.09 | ||||||
| FCF per share | $ | 0.12 | 0.51 | ||||||
| Free cash flow | $m | 28 | 116 | ||||||
| Net debt | $m | -15 | 61 | ||||||
| Book value equity | $m | 477 | 408 | ||||||
| Book value per share | $ | 1.95 | 1.77 | ||||||
| Number of shares | m | 244.9 | 230.34 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 30.40 | 13.40 | ||||||
| P/B LTM | x | 9.11 | 10.65 | ||||||
| P/S LTM | x | 8.52 | 8.48 | ||||||
| P/FCF LTM | x | 156.23 | 37.32 | ||||||
| EV/EBITDA LTM | x | 21.93 | 18.48 | ||||||
| EV/Sales LTM | x | 8.50 | 4.48 | ||||||
| Earnings Yield LTM | % | +3.29% | +7.46% | ||||||
| FCF Yield | % | +0.64% | +2.68% | ||||||
| Quality | |||||||||
| ROE | % | +30.78% | +39.59% | ||||||
| ROIC | % | +27.57% | +27.55% | ||||||
| Operating margin | % | +37.53% | +42.26% | ||||||
| Gross margin | % | +57.39% | +64.71% | ||||||
| FCF/Sales | % | +5.45% | +22.74% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -25.93% | -13.58% | ||||||
| Sales Growth YoY | % | +19.63% | +20.12% | ||||||
| Net Income Growth YoY | % | -25.67% | -14.53% | ||||||
| FCF Growth | % | -74.73% | +5.79% | ||||||
| Operating Profit Growth | % | +37.75% | +55.78% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.35 | 0.57 | ||||||
| Net Debt/EBITDA | x | -0.04 | 0.29 | ||||||
| EBIT/Net interest | x | 26.93 | 24.53 | ||||||
| Net debt/market cap | % | +1.66% | +8.82% | ||||||
| Net debt/Equity | x | -0.03 | 0.15 | ||||||
| Gross debt/equity | x | 0.17 | 0.50 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free